3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Renal Cell
38
Kidney Neoplasms
20
Melanoma
14
Neoplasm Metastasis
13
Prostatic Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Lymphoma
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Vaginal Neoplasms
1
Turcot syndrome
1
Skin Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Multiple Myeloma
1
Microsatellite Instability
1
Mesothelioma, Malignant
1
Interventions
pembrolizumab
18
Nivolumab
6
Radiotherapy
5
Paclitaxel
5
Trastuzumab
4
Specimen Handling
4
Ipilimumab
4
tisotumab vedotin
3
temsirolimus
3
olaparib
3
lenvatinib
3
X-Rays
3
Taxes
3
Surveys and Questionnaires
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Biopsy
3
spartalizumab
2
sargramostim
2
rucaparib
2
palbociclib
2
fludarabine
2
epacadostat
2
enzalutamide
2
durvalumab
2
cabozantinib
2
atezolizumab
2
aflibercept
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Interleukin-2
×
Genitourinary
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled